PT - JOURNAL ARTICLE AU - Zhuo, Jiachen AU - Raghavan, Prashant AU - Jiang, Li AU - Roys, Steven AU - Njonkou Tchoquessi, Rosy Linda AU - Chen, Hegang AU - Wickwire, Emerson M. AU - Parikh, Gunjan Y. AU - Schwartzbauer, Gary T. AU - Grattan, Lynn M. AU - Wang, Ze AU - Gullapalli, Rao P. AU - Badjatia, Neeraj TI - Longitudinal Assessment of Glymphatic Changes Following Mild Traumatic Brain Injury: Insights from PVS burden and DTI-ALPS Imaging AID - 10.1101/2024.06.01.24307927 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.01.24307927 4099 - http://medrxiv.org/content/early/2024/06/02/2024.06.01.24307927.short 4100 - http://medrxiv.org/content/early/2024/06/02/2024.06.01.24307927.full AB - Traumatic brain injury (TBI) even in the mild form may result in long-lasting post- concussion symptoms. TBI is also a known risk to late-life neurodegeneration. Recent studies suggest that dysfunction in the glymphatic system, responsible for clearing protein waste from the brain, may play a pivotal role in the development of dementia following TBI. Given the diverse nature of TBI, longitudinal investigations are essential to comprehending the dynamic changes in the glymphatic system and its implications for recovery. In this prospective study, we evaluated two promising glymphatic imaging markers, namely the enlarged perivascular space (ePVS) burden and Diffusion Tensor Imaging-based ALPS index, in 44 patients with mTBI at two early post-injury time points: approximately 14 days (14Day) and 6-12 months (6-12Mon) post-injury, while also examining their associations with post-concussion symptoms. Additionally, 37 controls, comprising both orthopedic patients and healthy individuals, were included for comparative analysis. Our key findings include: 1) White matter ePVS burden (WM- ePVS) and ALPS index exhibit significant correlations with age. 2) Elevated WM-ePVS burden in acute mTBI (14Day) is significantly linked to a higher number of post- concussion symptoms, particularly memory problems. 3) The increase in the ALPS index from acute (14Day) to the chronic (6-12Mon) phases in mTBI patients correlates with improvement in sleep measures. Furthermore, incorporating WM-ePVS burden and the ALPS index from acute phase enhances the prediction of chronic memory problems beyond socio-demographic and basic clinical information, highlighting their distinct roles in assessing glymphatic structure and activity. Early evaluation of glymphatic function could be crucial for understanding TBI recovery and developing targeted interventions to improve patient outcomes.Competing Interest StatementEMW has served as a scientific consultant to Axsome Therapeutics, DayZz, Ensodata, Eisai, Idorsia, Merck, Nox Health, Primasun, Purdue, and ResMed and is an equity shareholder in WellTap.Funding StatementThis study was funded by grants R01NS105503, R01NS105503-04S1, and R03NS088014 from the National Institute of Neurological Disorders and Stroke, W81XWH-24-CCCRP1 from the U. S. Air Force, HR001122s0043-RITMO-PA-006 from the Defense Advanced Research Projects Agency, and MTEC-20-13-IMAS-006 from the U. S. Army Medical Materiel Development Activity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee/IRB of the University of Maryland Baltimore gave IRB approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors